{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:30:39Z","timestamp":1790127039514,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jval.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:36:03Z","timestamp":1713324963000},"page":"1030-1038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne D.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Rosettie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Pinar","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2024.04.003_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/CCO.0000000000000403","article-title":"Role of stem cell transplant in lymphoma in the era of new drugs","volume":"29","author":"Benekou","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"15","key":"10.1016\/j.jval.2024.04.003_bib4","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jval.2024.04.003_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/PPO.0b013e31826aed4f","article-title":"Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?","volume":"18","author":"Lowry","year":"2012","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A\u00a0population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jval.2024.04.003_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jval.2024.04.003_bib8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ajh.26016","article-title":"Risk-adapted therapy in follicular lymphoma: is it time to \u201cFLEX\u201d","volume":"95","author":"Tobin","year":"2020","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.jval.2024.04.003_bib9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2024.04.003_bib10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ajh.24200","article-title":"Follicular lymphoma: 2015 update on diagnosis and management","volume":"90","author":"Freedman","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jval.2024.04.003_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jval.2024.04.003_bib12","first-page":"578","volume":"4","author":"Cognet","year":"2015"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jval.2024.04.003_bib14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2024.04.003_bib15","series-title":"Clinical study protocol: a phase 2 multicenter study of axicabtagene ciloleucel in subjects with relapsed\/refractory indolent non-Hodgkin lymphoma (iNHL. KTE-C19-105 (ZUMA-5)","author":"Avanzi","year":"2019"},{"issue":"suppl_5","key":"10.1016\/j.jval.2024.04.003_bib16","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jval.2024.04.003_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/2040620717738740","article-title":"The evolving role of targeted biological agents in the management of indolent B-cell lymphomas","volume":"8","author":"Wang","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"10.1016\/j.jval.2024.04.003_bib18","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.jval.2024.04.003_bib19","first-page":"1","article-title":"Refining the management of relapsed or refractory follicular lymphoma","volume":"18","author":"Pagel","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jval.2024.04.003_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jval.2024.04.003_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin\u2019s lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2024.04.003_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the Cost-Effectiveness of rituximab Maintenance and radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"issue":"15","key":"10.1016\/j.jval.2024.04.003_bib24","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1002\/cam4.3121","article-title":"Lenalidomide plus rituximab vs rituximab alone in relapsed or refractory indolent lymphoma: a cost-effectiveness analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.jval.2024.04.003_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdq582","article-title":"Treatment of follicular non-Hodgkin\u2019s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up","volume":"22","author":"Soini","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2024.04.003_bib26","series-title":"Rituximag for the treatment of relapsed follicular lymphoma. Single technology appraisal. Submission to National Institute for Health and Clinical Excellence (NICE)","year":"2007"},{"issue":"4","key":"10.1016\/j.jval.2024.04.003_bib27","first-page":"437","article-title":"A\u00a0budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States","volume":"25","author":"Appukkuttan","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.jval.2024.04.003_bib28","first-page":"960","article-title":"Cost-effectiveness of obinutuzumab plus Bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US","volume":"21","author":"Guzauskas","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2024.04.003_bib29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-018-0401-y","article-title":"Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with rituximab-Refractory Follicular Lymphoma in Norway","volume":"16","author":"Haukaas","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2024.04.003_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinthera.2012.02.019","article-title":"Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma","volume":"34","author":"Soini","year":"2012","journal-title":"Clin Ther"},{"issue":"15","key":"10.1016\/j.jval.2024.04.003_bib31","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib35","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.bbmt.2019.12.114","article-title":"Resource utilization and factors prolonging hospitalization for patients with refractory and relapsed B-cell lymphoma receiving axicabtagene ciloleucel (Axi-cel)","volume":"26","author":"Mian","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jval.2024.04.003_bib36","series-title":"Cancer Hospitalizations for Adults, 2009","author":"Price","year":"2012"},{"issue":"6","key":"10.1016\/j.jval.2024.04.003_bib38","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","article-title":"Health care costs for patients with cancer at the end of life","volume":"8","author":"Chastek","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jval.2024.04.003_bib40","series-title":"Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","author":"Jacobson","year":"2020"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jval.2024.04.003_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jval.2024.04.003_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737140.2023.2171994","article-title":"A\u00a024-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"23","author":"Palomba","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.jval.2024.04.003_bib45","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jval.2021.10.015","article-title":"Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1","volume":"25","author":"Vadgama","year":"2022","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2024.04.003_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2024.04.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S1098-3015(10)63491-2","article-title":"PCN62 utility elicitation in patients with follicular lymphoma","volume":"9","author":"Wild","year":"2006","journal-title":"Value Health"},{"issue":"13","key":"10.1016\/j.jval.2024.04.003_bib52","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2217\/fon.15.92","article-title":"Next-generation surveillance strategies for patients with lymphoma","volume":"11","author":"Cohen","year":"2015","journal-title":"Future Oncol"},{"issue":"25","key":"10.1016\/j.jval.2024.04.003_bib54","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"Morrison","year":"2018","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.jval.2024.04.003_bib55","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1634\/theoncologist.2018-0019","article-title":"Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin\u2019s lymphoma","volume":"24","author":"Reyes","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jval.2024.04.003_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv280","article-title":"Hospice use among patients with lymphoma: impact of disease aggressiveness and curability","volume":"108","author":"Odejide","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jval.2024.04.003_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2024.04.003_bib58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2024.04.003_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jval.2024.04.003_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/imt-2020-0161","article-title":"Neurological adverse events following CAR T-cell therapy: a real-world analysis","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.jval.2024.04.003_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.jval.2024.04.003_bib62","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T02:47:34Z","timestamp":1754016454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524023349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1098301524023349"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}